Patient Advocacy Unlocks Billions for ALS Research

WASHINGTON, DC – February 11, 2026 – The fight against Amyotrophic Lateral Sclerosis (ALS) received a monumental boost this month as patient advocacy group I AM ALS announced it had helped secure $313 million in federal funding for research in the 2026 budget. This infusion of capital marks the single largest annual investment in the disease's history and a major milestone for the organization's “Push for Progress” campaign, a three-year effort to raise $1 billion for ALS research.

The announcement underscores a dramatic shift in the landscape of medical research funding, where the collective voice of patients and their families has become a formidable force on Capitol Hill. Since its founding in 2019, I AM ALS has been at the forefront of this movement, helping to channel over $1.6 billion in federal dollars toward a disease long considered underfunded and overlooked.

This latest funding success arrives just as a new Government Accountability Office (GAO) report validates the effectiveness of the landmark Accelerating Access to Critical Therapies for ALS (ACT for ALS) Act. The confluence of record funding and positive legislative review signals a new era of hope and coordinated effort, yet it also casts a sharp light on the immense scientific and clinical hurdles that remain on the long road to a cure.

A New Era of Federal Investment

The newly allocated funds for Fiscal Year 2026, which congressional reports confirm total approximately $315 million, represent a coordinated, multi-agency assault on the disease. The package includes $90 million for the ACT for ALS Act implementation—a $15 million increase—and a steady $145 million for general ALS research at the National Institutes of Health (NIH). Crucially, it also directs a new $30 million investment from the Advanced Research Projects Agency for Health (ARPA-H), alongside sustained funding of $40 million from the Department of Defense's (DoD) medical research programs and $10 million for the Centers for Disease Control and Prevention's (CDC) National ALS Registry.

This financial commitment is a direct result of relentless advocacy from a coalition of groups including I AM ALS, The ALS Association, and the Muscular Dystrophy Association. Their strategy of elevating patient stories, building bipartisan support, and demanding bold investment has successfully transformed federal priorities.

“Our community of advocates and partners” were instrumental in securing the funds “to accelerate research, improve treatment access, and deliver real progress for people living with ALS,” I AM ALS stated in its announcement. The success of the “Push for Progress” campaign, now nearly one-third of the way to its ambitious $1 billion goal, demonstrates a powerful new model for how grassroots movements can drive systemic change and secure the resources needed to tackle intractable diseases.

The ACT for ALS: A Legislative Game-Changer

Central to this progress is the ACT for ALS Act, signed into law on December 23, 2021. The legislation was designed to dismantle barriers in drug development and expand patient access to promising, unapproved therapies. Its success, detailed in a GAO report released on February 4, 2026, offers a potential blueprint for other rare diseases.

The GAO's evaluation confirms the Act is working as intended. Between fiscal years 2022 and 2025, the NIH and FDA awarded approximately $276 million to implement its key provisions. These include funding Expanded Access Programs (EAPs), which provide investigational drugs to patients who do not qualify for clinical trials. According to the report, these programs are expected to give roughly 750 individuals with ALS access to potential treatments across 46 clinic sites, significantly expanding the geographic and demographic reach of cutting-edge research.

Furthermore, the Act established a critical public-private partnership between the NIH and FDA to streamline therapy development. This collaboration has already led to the creation of a centralized ALS Knowledge Portal, launched in August 2025, to promote open science and data sharing. The GAO found that this partnership is improving coordination between federal agencies and building a more robust research ecosystem, preparing more clinics to participate in future clinical trials and generating high-quality data from a broader patient population.

With the initial authorization for the ACT for ALS set to expire after 2026, advocates are already turning their attention to the next legislative battle: reauthorization. Ensuring this framework continues is seen as essential to maintaining the current research momentum.

Balancing Hope with Scientific Hurdles

While the influx of funding and legislative success provides unprecedented hope, it does not erase the daunting scientific complexity of ALS. The disease is notoriously heterogeneous, with diverse genetic and environmental triggers, making a one-size-fits-all treatment elusive. Researchers still grapple with fundamental challenges, such as bypassing the blood-brain barrier to deliver drugs effectively to motor neurons and the significant delays—often over a year—in reaching a definitive diagnosis.

The path from lab to patient is fraught with failure. The ALS community was reminded of this harsh reality when Amylyx Pharmaceuticals voluntarily withdrew its approved drug, Relyvrio, from the market in 2024 after a large-scale confirmatory trial failed to show a clinical benefit. The episode highlighted the difficult balance the FDA must strike between providing early access to promising therapies for a fatal disease and demanding rigorous scientific proof of efficacy.

Despite these challenges, the current momentum is undeniable. The combination of historic funding, an effective legislative framework, and a mobilized patient community has created a powerful engine for progress. The new funds will fuel innovative approaches, from gene-targeted therapies to novel antibody discovery, while the infrastructure built by the ACT for ALS promises to make research smarter, faster, and more inclusive. For the thousands living with the disease and their families, that progress cannot come soon enough.